Core Insights - The company will present preclinical data on its oral, potent pan-KRAS inhibitor JAB-23E73 at the 2025 AACR-NCI-EORTC conference in Boston from October 22 to October 26, 2025 [1] - The abstract will be released on October 22, 2025, and the poster will be displayed on October 23, 2025, highlighting the drug's selectivity and efficacy [1] Company Overview - JAB-23E73 demonstrates exceptional antitumor activity across various cancer types with different KRAS mutations or amplifications [2] - The drug effectively induces tumor regression in KRAS-driven mouse tumor models without significant weight changes, indicating good tolerability and a wide therapeutic window [2] - JAB-23E73 has favorable pharmacokinetic characteristics for oral administration, with its tumor p-ERK inhibition regulated by plasma concentration [2] - Phase I clinical trials for JAB-23E73 targeting advanced solid tumors with KRAS mutations are currently underway in China and the United States [2]